Executive Summary

This "Basic Platform Report: Leukemia Therapeutics" report provides a complete and systematic description of the current R&D activities of already established as well as new innovative therapies for the treatment of leukemia (ALL CLL, AML and CML). This informative report includes extensive presentations of more than 60 of the most important companies active in this field. The focus has been to review the R&D activities and partnerships in different therapeutic strategies. Hundreds of pipeline drugs and a majority of B2B collaboration and industry-academic alliances are included.

Each company profile contains contact data, a short description of the company, partnership activities, pipeline activities, patents and description of products already at market.

With the help of the company index of more than 60 firms collaborations can easily be track down any player in the field identified. The "Basic Platform Report: Leukemia Therapeutics" is an excellent source of information that provides you with a solid presentation of this exciting and rapidly evolving field.

Related patents Some of the drugs included in the report:

AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999

Some of the companies included in the report: Aventis, Antigenics, Biogen/ IDEC, Berlex Laboratories, Inc., Corixa Corporation, Celgene Corporation, Chiron, Cephalon Inc, Genentech, Exelixis Inc, Genta Incorporated, GlaxoSmithKline, ILEX Oncology Inc., Immuno-Designed Molecules, IDM, Immunex Corp, J&J PRD, Ligand Pharmaceuticals, Maxim Pharmaceuticals, Medarex, Merck, Millennium Pharma., Novartis, OSI Pharmaceuticals, Point Therapeutics, Protein Design Labs, Pfizer (Pharmacia), Pharmatech Oncology, Pharmasset, Inc., Pharmacyclics, Schering-Plough, Supergen, Roche, Schering AG, Schering Corporation, Shire Pharmaceuticals, Seragen, Vion Pharmaceuticals, Inc.

Related Reports:
Prostate Cancer Drug Discoveries: What the Future Holds
Competitor Analysis: TGF-R Agonists and Antagonists
CDK Inhibitors Patent Landscape 2009
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Blood, Organ & Ambulatory Health Services in the US - Industry Risk Rating Report
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Top 20 Cancer Therapy Brands Forecast
Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
Strategic Analysis of the Bladder Cancer Therapeutics